

DAFTAR PUSTAKA

1. Ahmed, S. et al. (2014) 'Advances in the management of colorectal cancer: From biology to treatment', *International Journal of Colorectal Disease*, 29(9), pp. 1031–1042. doi: 10.1007/s00384-014-1928-5.
2. Ajouz, H., Mukherji, D. and Shamseddine, A. (2014) 'Secondary bile acids: An underrecognized cause of colon cancer', *World Journal of Surgical Oncology*, 12(1), pp. 1–5. doi: 10.1186/1477-7819-12-164.
3. Alzahrani, S. M., Al Doghaither, H. A. and Al-Ghafar, A. B. (2021) 'General insight into cancer: An overview of colorectal cancer (review)', *Molecular and Clinical Oncology*, 15(6). doi: 10.3892/MCO.2021.2433.
4. Amersi, F., Agustin, M. and Ko, C. Y. (2006) 'Colorectal cancer: Epidemiology and health services research', *Surgical Oncology Clinics of North America*, 15(1), pp. 21–37. doi: 10.1016/j.soc.2005.08.003.
5. Annaházi, A. et al. (2013) 'Fecal MMP-9: A new noninvasive differential diagnostic and activity marker in ulcerative colitis', *Inflammatory Bowel Diseases*, 19(2), pp. 316–320. doi: 10.1002/ibd.22996.
6. Aran, V. et al. (2016) 'Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality', *Clinical Colorectal Cancer*, 15(3), pp. 195–203. doi: 10.1016/j.clcc.2016.02.008.
7. Arnold, M. et al. (2017) 'Global patterns and trends in colorectal cancer incidence and mortality', *Gut*, 66(4), pp. 683–691. doi: 10.1136/gutjnl-2015-310912.
8. Arshita, N. et al. (2018) 'The tendency of having MSH2 and MSH6 microsatellite instability among clinicopathological features in patients with colorectal cancer', *Asian Pacific Journal of Cancer Prevention*, 19(11), pp. 3147–3152. doi: 10.31557/APJCP.2018.19.11.3147.
9. Bahardoust, M. et al. (2023) 'The Association between ABO Blood Group and the Risk of Colorectal Cancer: A Systematic Literature Review and Meta-

Analysis', Asian Pacific Journal of Cancer Prevention, 24(8), pp. 2555–2563. doi: 10.31557/APJCP.2023.24.8.2555.

10. Bertagnolli, M. M. et al. (2009) 'Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and leukemia group B protocol 89803', Journal of Clinical Oncology, 27(11), pp. 1814–1821. doi: 10.1200/JCO.2008.18.2071.
11. Bertero, L. et al. (2018) 'Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria—What has changed and why?', Virchows Archiv, 472(4), pp. 519–531. doi: 10.1007/s00428-017-2276-y.
12. Bevan, R. and Rutter, M. D. (2018) 'Colorectal Cancer Screening — Who , How , and When ?', Clin Endosc, 51, pp. 37–49.
13. Bhattarai, M. et al. (2020) 'MLH1 and MSH2 mismatch repair protein profile using immunohistochemistry in Nepalese colorectal cancer patients', Medical Journal of Indonesia, 29(2), pp. 183–189. doi: 10.13181/mji.oa.203633.
14. Brar, B. et al. (2021) 'Nanotechnology in Colorectal Cancer for Precision Diagnosis and Therapy', Frontiers in Nanotechnology, 3(September), pp. 1–21. doi: 10.3389/fnano.2021.699266.
15. Bray, F. et al. (2015) 'Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration', International Journal of Cancer, 137(9), pp. 2060–2071. doi: 10.1002/ijc.29670.
16. Bronchud, M. et al. (2000) 'Molecular Basis of Cancer', The Lancet, 356(Oct 14), p. 2000. doi: 10.1016/s0140-6736(05)74283-5.
17. Brown, K. G. M. et al. (2019) 'Management of colorectal cancer', The BMJ, 366(August), pp. 1–7. doi: 10.1136/bmj.l4561.

18. Brzacki, V. et al. (2019) 'Diabetes Mellitus: a Clinical Condition Associated with Metabolic Syndrome and Colorectal Cancer Risk', *Current Pharmacology Reports*, 5(4), pp. 205–209. doi: 10.1007/s40495-019-00183-8.
19. Carethers, J. M. and Doubeni, C. A. (2020) 'Causes of Socioeconomic Disparities in Colorectal Cancer and Intervention Framework and Strategies', *Gastroenterology*, 158(2), pp. 354–367. doi: 10.1053/j.gastro.2019.10.029.
20. Carr, P. R. et al. (2018) 'Lifestyle factors and risk of sporadic colorectal cancer by microsatellite instability status: A systematic review and meta-analyses', *Annals of Oncology*, 29(4), pp. 825–834. doi: 10.1093/annonc/mdy059.
21. Chen, S. et al. (2023) 'Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories from 2020 to 2050', *JAMA Oncology*, 9(4), pp. 465–472. doi: 10.1001/jamaoncol.2022.7826.
22. Cheng, Y., Ling, Z. and Li, L. (2020) 'The Intestinal Microbiota and Colorectal Cancer', *Frontiers in Immunology*, 11(November), pp. 1–13. doi: 10.3389/fimmu.2020.615056.
23. Chowdhury, M. R. et al. (2024) 'Optimizing Fecal Occult Blood Test (FOBT) Colorectal Cancer Screening Using Gut Bacteriome as a Biomarker', *Clinical Colorectal Cancer*, 23(1), pp. 22–34.e2. doi: 10.1016/j.clcc.2023.10.004.
24. Cisterna, B. A. et al. (2016) 'Targeted nanoparticles for colorectal cancer', *Nanomedicine*, 11(18), pp. 2443–2456. doi: 10.2217/nnm-2016-0194.
25. Daly, M. C. and Paquette, I. M. (2019) 'Surveillance, Epidemiology, and End Results (SEER) and SEER-Medicare Databases: Use in Clinical Research for Improving Colorectal Cancer Outcomes', *Clinics in Colon and Rectal Surgery*, 32(1), pp. 61–68. doi: 10.1055/s-0038-1673355.
26. Dong, L. et al. (2021) 'Cytoplasmic MSH2 Related to Genomic Deletions in the MSH2/EPCAM Genes in Colorectal Cancer Patients With Suspected Lynch Syndrome', *Frontiers in Oncology*, 11(May), pp. 1–11. doi: 10.3389/fonc.2021.627460.

27. Ekundina, V. . et al. (2023) ‘Immunohistochemical Expression of MSH6 and MSH2 in Colorectal Cancer’, Archives of Medical Case Reports and Case Study, 7(January). doi: 10.31579/2692-9392/170.
28. Ferlay, J. et al. (2021) ‘Cancer statistics for the year 2020: An overview’, International Journal of Cancer, 149(4), pp. 778–789. doi: 10.1002/ijc.33588.
29. Fleming, M. et al. (2012) ‘Colorectal carcinoma: Pathologic aspects’, Journal of Gastrointestinal Oncology, 3(3), pp. 153–173. doi: 10.3978/j.issn.2078-6891.2012.030.
30. Ford, A. C. et al. (2008) ‘Diagnostic utility of alarm features for colorectal cancer: Systematic review and meta-analysis’, Gut, 57(11), pp. 1545–1552. doi: 10.1136/gut.2008.159723.
31. Gandomani, H. S. et al. (2017) ‘Colorectal cancer in the world: incidence, mortality and risk factors’, Biomedical Research and Therapy, 4(10), p. 1656. doi: 10.15419/bmrat.v4i10.372.
32. Guo, L. et al. (2023) ‘Correlation of MLH1 and MSH2 levels with clinicopathologic characteristics in colorectal cancer’, Am J Transl Res, 15(2), pp. 1107–1116. Available at: www.ajtr.org.
33. Gupta, S. et al. (2020) ‘Recommendations for Follow-Up after Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer’, American Journal of Gastroenterology, 115(3), pp. 415–434. doi: 10.14309/ajg.0000000000000544.
34. Guraya, S. (2014) ‘Chemopreventive role of vitamin D in colorectal carcinoma’, Journal of Microscopy and Ultrastructure, 2(1), p. 1. doi: 10.1016/j.jmau.2013.09.001.
35. Hammond, W. A., Swaika, A. and Mody, K. (2016) ‘Pharmacologic resistance in colorectal cancer: A review’, Therapeutic Advances in Medical Oncology, 8(1), pp. 57–84. doi: 10.1177/1758834015614530.

36. Hnatyszyn, A. et al. (2019) 'Colorectal carcinoma in the course of inflammatory bowel diseases', *Hereditary Cancer in Clinical Practice*, 17(1), pp. 1–9. doi: 10.1186/s13053-019-0118-4.
37. Hossain, M. S. et al. (2022) 'Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies', *Cancer*, 14(1732), pp. 1–25.
38. Howe, J. R. and Guillem, J. G. (1997) 'The genetics of colorectal cancer', *Surgical Clinics of North America*, 77(1), pp. 175–179. doi: 10.1007/978-1-4614-8412-7_1.
39. Hu, X. et al. (2018) 'Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers', *Chinese Journal of Pathology*, 47(11), pp. 827–833. doi: 10.3760/cma.j.issn.0529-5807.2018.11.003.
40. Huyghe, N. et al. (2022) 'Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine', *Cancers*, 14(9). doi: 10.3390/cancers14092241.
41. Issa, I. A. and Noureddine, M. (2017) 'Colorectal cancer screening: An updated review of the available options', *World Journal of Gastroenterology*, 23(28), pp. 5086–5096. doi: 10.3748/wjg.v23.i28.5086.
42. Jaballah-Gabteni, A. et al. (2019) 'Identification of novel pathogenic MSH2 mutation and new DNA repair genes variants: Investigation of a Tunisian Lynch syndrome family with discordant twins', *Journal of Translational Medicine*, 17(1), pp. 1–13. doi: 10.1186/s12967-019-1961-9.
43. Jeo, W. and Subrata, F. (2020) 'The Survival Rate of Colorectal Cancer in dr. Cipto Mangunkusumo Hospital', *The New Ropanasuri : Journal of Surgery*, 5(2), pp. 13–17. doi: 10.7454/nrjs.v5i2.1081.
44. Johdi, N. A. and Sukor, N. F. (2020) 'Colorectal Cancer Immunotherapy: Options and Strategies', *Frontiers in Immunology*, 11(September), pp. 1–18. doi: 10.3389/fimmu.2020.01624.

45. Kenney, B., Deng, Y. and Mitchell, K. (2013) 'Expression of p27, COX-2, MLH1, and MSH2 in young patients with colon carcinoma and correlation with morphologic findings', *Human Pathology*, 44(4), pp. 591–597. doi: 10.1016/j.humpath.2012.07.003.
46. Keum, N. N. and Giovannucci, E. (2019) 'Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies', *Nature Reviews Gastroenterology and Hepatology*, 16(12), pp. 713–732. doi: 10.1038/s41575-019-0189-8.
47. Kitsel, Y. et al. (2023) 'Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies', *Cancers*, 15(6), p. 1679. doi: 10.3390/cancers15061679.
48. Kolligs, F. T. (2016) 'Diagnostics and epidemiology of colorectal cancer', *Visceral Medicine*, 32(3), pp. 158–164. doi: 10.1159/000446488.
49. Kranenburg, O., Speeten, K. van der and Hingh, I. de (2021) 'Peritoneal Metastases From Colorectal Cancer: Defining and Addressing the Challenges', *Frontiers in Oncology*, 11(March), pp. 1–11. doi: 10.3389/fonc.2021.650098.
50. Krasteva, N. and Georgieva, M. (2022) 'Promising Therapeutic Strategies for Colorectal Cancer Treatment Based on Nanomaterials', *Pharmaceutics*, 14(6), pp. 1–38. doi: 10.3390/pharmaceutics14061213.
51. Lanza, G. et al. (2006) 'Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients', *Journal of Clinical Oncology*, 24(15), pp. 2359–2367. doi: 10.1200/JCO.2005.03.2433.
52. Lanza, G. et al. (2007) 'mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer', *Molecular Cancer*, 6, pp. 1–11. doi: 10.1186/1476-4598-6-54.

53. Lawler, M. et al. (2019) Colorectal Cancer. Sixth Edit, Abeloff's Clinical Oncology. Sixth Edit. Elsevier Inc. doi: 10.1016/B978-0-323-47674-4.00074-8.
54. Van Lier, M. G. F. et al. (2012) Peutz-Jeghers syndrome and family planning: The attitude towards prenatal diagnosis and pre-implantation genetic diagnosis, European Journal of Human Genetics. doi: 10.1038/ejhg.2011.152.
55. Lusikooy, R. (2017) Faktor Resiko Terjadinya Kanker Kolorektal di Indonesia. Hasanuddin University.
56. Ma, Y. et al. (2018) 'Type 2 diabetes and risk of colorectal cancer in two large U.S. prospective cohorts', British Journal of Cancer, 119(11), pp. 1436–1442. doi: 10.1038/s41416-018-0314-4.
57. Makmun, D. et al. (2014) 'Changing trends in gastrointestinal malignancy in Indonesia: The Jakarta experience', Journal of Cancer Research & Therapy, 2(9), pp. 160–168. doi: 10.14312/2052-4994.2014-24.
58. Mármol, I. et al. (2017) 'Colorectal carcinoma: A general overview and future perspectives in colorectal cancer', International Journal of Molecular Sciences, 18(1). doi: 10.3390/ijms18010197.
59. Mendis, S. et al. (2022) 'Biology and Clinical Implications of Fecal Occult Blood Test Screen-Detected Colorectal Cancer', JNCI Cancer Spectrum, 6(1), pp. 1–10. doi: 10.1093/jncics/pkab100.
60. Mohamed, S. A.-A. et al. (2023) 'Expression status of MLH1 and MSH2 mismatch repair proteins in colorectal carcinoma', Egyptian Journal of Pathology, 43(1), pp. 8–13. doi: 10.4103/egjp.egjp_1_23.
61. Morgan, E. et al. (2020) 'Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN', Gut, 72(2).
62. Nagtegaal, I. D. et al. (2020) 'The 2019 WHO classification of tumours of the digestive system', Histopathology, 76(2), pp. 182–188. doi: 10.1111/his.13975.

63. National Cancer Institute (2022) 'Financial Burden of Cancer Care', Cancer Trends Progress Report, Updated Ap. Available at: https://progressreport.cancer.gov/after/economic_burden#field_most_recent_estimates.
64. Nguyen, T. T. et al. (2018) 'Role of bile acids in colon carcinogenesis', *World J Clin Cases*, 9(9), pp. 157–164.
65. Nojadeh, J. N., Sharif, S. B. and Sakhinia, E. (2018) 'Microsatellite instability in colorectal cancer', *EXCLI Journal*, 17, pp. 159–168. doi: 10.17179/excli2017-948.
66. Palimaka, S., Blackhouse, G. and Goeree, R. (2015) 'Colon capsule endoscopy for the detection of colorectal polyps: An economic analysis', *Ontario Health Technology Assessment Series*, 15(15), pp. 1–43.
67. Pang, Y. et al. (2018) 'Diabetes, plasma glucose and incidence of colorectal cancer in Chinese adults: A prospective study of 0.5 million people', *Journal of Epidemiology and Community Health*, 72(10), pp. 919–925. doi: 10.1136/jech-2018-210651.
68. Peeters, P. J. H. L. et al. (2015) 'The risk of colorectal cancer in patients with type 2 Diabetes: Associations with treatment stage and obesity', *Diabetes Care*, 38(3), pp. 495–502. doi: 10.2337/dc14-1175.
69. Price, S. and Wilson, L. (2016) *Patofisiologi Konsep Klinis dan Proses-Proses Penyakit*. 6th edn. Jakarta: Penerbit Buku KEdokteran EGC.
70. Purnomo, H. D. et al. (2023) 'Colorectal cancer screening in Semarang, Indonesia: A multicenter primary health care based study', *PLoS ONE*, 18(1 January), pp. 1–12. doi: 10.1371/journal.pone.0279570.
71. Randrian, V., Evrard, C. and Tougeron, D. (2021) 'Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies', *Cancers*, 13(12), pp. 1–18.

72. Rashid, G. et al. (2023) 'ABO and Rhesus blood group markers as predictors in colorectal cancer: A prospective observational study', *Medicine (United States)*, 102(47), p. E36256. doi: 10.1097/MD.00000000000036256.
73. Rawla, P., Sunkara, T. and Barsouk, A. (2019) 'Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors', *Przegląd Gastroenterologiczny*, 14(2), pp. 89–103. doi: 10.5114/pg.2018.81072.
74. Sawicki, T. et al. (2021) 'A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis', *Cancers*, 13(9), pp. 1–23. doi: 10.3390/cancers13092025.
75. Schreuders, E. H. et al. (2015) 'Colorectal cancer screening: A global overview of existing programmes', *Gut*, 64(10), pp. 1637–1649. doi: 10.1136/gutjnl-2014-309086.
76. Sehgal, R. et al. (2014) 'Lynch Syndrome: An updated review', *Genes*, 5(3), pp. 497–507. doi: 10.3390/genes5030497.
77. Shussman, N. and Wexner, S. D. (2014) 'Colorectal polyps and polyposis syndromes', *Gastroenterology Report*, 2(1), pp. 1–15. doi: 10.1093/gastro/got041.
78. Siena, S. et al. (2009) 'Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer', *Journal of the National Cancer Institute*, 101(19), pp. 1308–1324. doi: 10.1093/jnci/djp280.
79. Silinskaite, U. et al. (2023) 'A Novel Mutation of MSH2 Gene in a Patient with Lynch Syndrome Presenting with Thirteen Metachronous Malignancies', *Journal of Clinical Medicine*, 12(17). doi: 10.3390/jcm12175502.
80. Sugiyono (2021) *Metode penelitian kuantitatif, kualitatif, dan R&D*. 3rd edn. Bandung: Alfabeta.
81. Sung, H. et al. (2021a) 'Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185

- Countries', CA: A Cancer Journal for Clinicians, 71(3), pp. 209–249. doi: 10.3322/caac.21660.
82. Sung, H. et al. (2021b) 'Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries', CA: A Cancer Journal for Clinicians, 71(3), pp. 209–249. doi: 10.3322/caac.21660.
 83. Tariq, K. and Ghias, K. (2016) 'Colorectal cancer carcinogenesis: a review of mechanisms', Cancer Biology and Medicine, 13(1), pp. 120–135. doi: 10.28092/j.issn.2095-3941.2015.0103.
 84. Thélin, C. and Sikka, S. (2015) 'Epidemiology of Colorectal Cancer — Incidence, Lifetime Risk Factors Statistics and Temporal Trends', Screening for Colorectal Cancer with Colonoscopy, (Table 1). doi: 10.5772/61945.
 85. Valle, L. et al. (2019) 'Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine', J Pathol, 247(5), pp. 574–588. doi: 10.1002/path.5229.Genetic.
 86. Wang, S. M. et al. (2019) 'Clinical significance of MLH1/MSH2 for stage II/III sporadic colorectal cancer', World Journal of Gastrointestinal Oncology, 11(11), pp. 1065–1080. doi: 10.4251/wjgo.v11.i11.1065.
 87. WHO (2020) Cancer Indonesia 2020 Country Profile, Cancer Country Profile. doi: 10.1016/S0366-0850(07)80117-7.
 88. Win, A. K. et al. (2012) 'Risk prediction models for colorectal cancer: A review', Cancer Epidemiology Biomarkers and Prevention, 21(3), pp. 398–410. doi: 10.1158/1055-9965.EPI-11-0771.
 89. Wong, M. C. S. et al. (2021) 'Differences in Incidence and Mortality Trends of Colorectal Cancer Worldwide Based on Sex, Age, and Anatomic Location', Clinical Gastroenterology and Hepatology, 19(5), pp. 955-966.e61. doi: 10.1016/j.cgh.2020.02.026.
 90. World Health Organisation (2020) World Health Statistics 2020: Monitoring Health for the SDGs, Sustainable Development Goals. Available at:

<https://all3dp.com/2/fused-deposition-modeling-fdm-3d-printing-simply-explained/>.

91. Young, P. E. et al. (2014) 'Early detection of colorectal cancer recurrence in patients undergoing surgery with curative intent: Current status and challenges', *Journal of Cancer*, 5(4), pp. 262–271. doi: 10.7150/jca.7988.
92. Zhang, Y. et al. (2017) 'Cholecystectomy can increase the risk of colorectal cancer: A meta-analysis of 10 cohort studies', *PLoS ONE*, 12(8), pp. 1–17. doi: 10.1371/journal.pone.0181852.
93. Zheng, S. et al. (2023) 'Effectiveness of Colorectal Cancer (CRC) Screening on All-Cause and CRC-Specific Mortality Reduction: A Systematic Review and Meta-Analysis', *Cancers*, 15(7). doi: 10.3390/cancers15071948.